Open questions in the management of mantle cell lymphoma

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 602-609

  Li, Zhi Ming ^a,b   Zucca, Emanuele ^a   Ghielmini, Michele ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Conventional therapy; First line therapy; Intensive therapy; Mantle cell lymphoma

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; INTERFERON; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; TRANSCRIPTION FACTOR SOX11; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FAILURE FREE SURVIVAL; GASTROINTESTINAL ENDOSCOPY; GRAFT VERSUS LYMPHOMA EFFECT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IONIZING RADIATION; LUMBAR PUNCTURE; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR LOCALIZATION;

HUMANS; LYMPHOMA, MANTLE-CELL; PROGNOSIS;

EID: 84878905066     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.013     Document Type: Review

References (90)

1. Swerdlow S.H., Campo E., Seto M., Müller-Hermelink H.K. Mantle cell lymphoma. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues 2008, 229-232. IARS Press. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Leonard J.P., Williams M.E., Goy A., et al. Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma 2009, 9:267-277.
3. Chandran R., Gardiner S.K., Simon M., Spurgeon S.E. Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007. Leuk Lymphoma 2012, 53:1488-1493.
4. Ghielmini M., Zucca E. How I treat mantle cell lymphoma. Blood 2009, 114:1469-1476.
5. Nygren L., Baumgartner Wennerholm S., Klimkowska M., Christensson B., Kimby E., Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012, 119:4215-4223.
6. Fu K., Weisenburger D.D., Greiner T.C., et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315-4321.
7. Wlodarska I., Dierickx D., Vanhentenrijk V., et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008, 111:5683-5690.
8. Cortelazzo S., Ponzoni M., Ferreri A.J., Dreyling M. Mantle cell lymphoma. Crit Rev Oncol Hematol 2012, 82:78-101.
9. Vose J.M. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012, 87:604-609.
10. Kluin-Nelemans H.C., Doorduijn J.K. Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 2011, 48:208-213.
11. Harel S., Delarue R., Ribrag V., Dreyling M., Hermine O. Treatment of younger patients with mantle cell lymphoma. Semin Hematol 2011, 48:194-207.
12. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
13. Bosch F., López-Guillermo A., Campo E., et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567-575.
14. Valdez R., Kroft S.H., Ross C.W., Schnitzer B., Singleton T.P., Peterson L.C., et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 2002, 15:1073-1079.
15. Salar A., Juanpere N., Bellosillo B., et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006, 30:1274-1280.
16. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
17. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
18. Hartmann E., Fernàndez V., Moreno V., et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008, 26:4966-4972.
19. Iqbal J., Shen Y., Liu Y., et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012, 119:4939-4948.
20. Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology 2012;May 29. [Epub ahead of print].
21. Wang X., Asplund A.C., Porwit A., Flygare J., Smith C.I., Christensson B., et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008, 143:248-252.
22. Fernàndez V., Salamero O., Espinet B., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 70:1408-1418.
23. Martin P., Chadburn A., Christos P., et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009, 27:1209-1213.
24. Teodorovic I., Pittaluga S., Kluin-Nelemans J.C., et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819-2826.
25. Unterhalt M., Herrmann R., Tiemann M., et al. Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 1996, 10:836-843.
26. Howard O.M., Gribben J.G., Neuberg D.S., Grossbard M., Poor C., Janicek M.J., et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-1294.
27. Chang J.E., Peterson C., Choi S., et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011, 155:190-197.
28. Ruan J., Martin P., Furman R.R., et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011, 29:690-697.
29. Smith MR, Li H, Gordon L, et al. Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012;Jul 30. [Epub ahead of print].
30. Meusers P., Engelhard M., Bartels H., et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989, 7:365-380.
31. Nickenig C., Dreyling M., Hoster E., et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006, 107:1014-1022.
32. Herold M., Haas A., Doerken B., et al. Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone: 50 months up date of the OSHO phase III study (OSHO#39). Ann Oncol 2008, 19. iv86 (Abstract 012).
33. Rummel M., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009, 114. (Abstract 405).
34. Kluin-Nelemans J.C., Hoster E., Walewski J., et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Blood 2011, 118. (Abstract 439).
35. Kluin-Nelemans H.C., Hoster E., Hermine O., et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012, 367:520-531.
36. Khouri I.F., Romaguera J., Kantarjian H., et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
37. Romaguera J.E., Khouri I.F., Kantarjian H.M., et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000, 39:77-85.
38. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
39. Epner E.M., Unger J., Miller T., et al. A multicenter trial of hyper-CVAD+rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007, 110:121a. (Abstract 387).
40. Merli F., Luminari S., Ilariucci F., et al. Rituximab plus hypercvad alternating with high dose methotrexate and cytarabine for patients with newly diagnosed mantle cell lymphoma. a multicenter trial from GISL. Blood 2008, 112. (Abstract 3050).
41. Merli F., Luminari S., Ilariucci F., et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from gruppo italiano studio linfomi. Br J Haematol 2012, 156:346-353.
42. de Guibert S., Jaccard A., Bernard M., Turlure P., Bordessoule D., Lamy T. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006, 91:425-426.
43. Lefrère F., Delmer A., Suzan F., et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587-593.
44. Dreger P., Rieger M., Seyfarth B., Hensel M., Kneba M., Ho A.D., et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007, 92:42-49.
45. Van't Veer M.B., de Jong D., MacKenzie M., Kluin-Nelemans H.C., Van Oers M.H., Zijlstra J., et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009, 144:524-530.
46. Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA. Blood 2012 Jun 20. [Epub ahead of print].
47. Geisler C.H., Kolstad A., Laurell A., et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012, 158:355-362.
48. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
49. Hoster E., Unterhalt M., Wormann B., et al. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. Blood 2008, 112. (Abstract 3049).
50. Dreyling M.H., Hoster E., Hoof A.V., et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: long term follow up of a randomized trial of the. Blood 2008, 112. (Abstract 769).
51. Dreyling M., Hoster E., Hermine O., et al. European Mantle Cell Lymphoma Network: an update on current first line trials [abstract]. Ann Oncol 2008, 19:300. Ann Oncol 2008;19 (Abstract 300).
52. Hermine O., Hoster E., Walewski J., et al. Alternating courses of 3× CHOP and 3× DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2010, 116. (Abstract 110).
53. Romaguera J.E., Fayad L.E., Feng L., et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010, 150:200-208.
54. Ghielmini M., Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705-711.
55. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706-714.
56. LaCasce A.S., Vandergrift J.L., Rodriguez M.A., et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database. Blood 2012, 119:2093-2099.
57. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
58. Pott C., Schrader C., Gesk S., et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271-2277.
59. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
60. Kluin-Nelemans J.C., Hoster E., Hermine O., et al. R-CHOP versus R-FC followed maintenance with rituximab or IFN: first results of a randomized trial for elderly patients with mantle cell lymphoma. Ann Oncol 2011, 22(Suppl 4). (Abstract 016).
61. Herold M., Schulze A., Niederwieser D., et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006, 132:105-112.
62. Ferrer A., Bosch F., Villamor N., et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008, 19:135-141.
63. Gill S., Herbert K.E., Prince H.M., et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009, 147:83-88.
64. Oinonen R., Franssila K., Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999, 78:145-149.
65. Conconi A., Franceschetti S., Lobetti-Bodoni C., et al. Central nervous system (CNS) relapse in a population of 143 patients (Pts) with mantle cell lymphoma (MCL) from two centers. Blood (ASH Annual Meeting Abstracts) 2011, 118:2660.
66. Cheah C., George A., Gine E., et al. Incidence, characteristics and outcome of CNS involvement in mantle cell lymphoma: a multicentre retrospective analysis from the European Mantle Cell Lymphoma Network. Haematologica 2012, 97(Suppl 1). (Abstract 1112).
67. Brugger W., Hirsch J., Grünebach F., et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004, 15:1691-1698.
68. Andersen N.S., Pedersen L.B., Laurell A., et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009, 27:4365-4370.
69. Forstpointner R., Unterhalt M., Dreyling M., et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003-4008.
70. Le Gouill S., Thieblemont C., Gyon E., et al. High response rate after 4 courses of R-DHAP in untreated mantle cell lymphoma (MCL) patients in the ongoing phase III randomized GOELAMS and GELA LyMa Trial. Blood 2010, 116. (Abstract 1758).
71. Leitch H.A., Gascoyne R.D., Chhanabhai M., et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003, 14:1555-1561.
72. Rosenbluth B.D., Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiat Oncol Biol Phys 2006, 65:1185-1191.
73. Beaven A.W., Rizzieri D.A., Powell Z., et al. High complete response rates with dose dense/dose intense chemotherapy plus radioimmunotherapy in high risk diffuse large B cell and mantle cell lymphoma. Blood 2011, 118. (Abstract 2681).
74. Gill S., Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008, 49:398-409.
75. Milpied N., Gaillard F., Moreau P., et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645-650.
76. Peterlin P., Leux C., Gastinne T., et al. Autologous stem cell transplantation in mantle cell lymphoma: total body irradiation (TBI) plus cyclophosphamide (or melphalan) is not superior to beam, a single institution experience. Blood 2010, 116. (Abstract 3563).
77. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793-800.
78. Rubio M.T., Boumendil A., Luan J.J., et al. Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the Lymphoma Working Party of the EBMT. Blood 2010, 116. (Abstract 688).
79. Le Gouill S, Kröger N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012 Mar 22. [Epub ahead of print].
80. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
81. Kasamon Y.L., Jones R.J., Diehl L.F., et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005, 11:39-46.
82. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20(3):520-525.
83. Houot R., Le Gouill S., Ojeda Uribe M., et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol 2012, 23:1555-1561.
84. Murawski N., Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010, 11:1074-1085.
85. Dang N.H., Hagemeister F.B., Pro B., et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:4095-4102.
86. Reeder C.B., Witzig T.E., Zinzani P.L., et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003). J Clin Oncol 2009, 27. (Abstract a8569).
87. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
88. Witzig T.E., Vose J.M., Zinzani P.L., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
89. Wang M., Fayad L., Wagner-Bartak N., et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012, 13(7):716-723.
90. Zaja F., De Luca S., Vitolo U., et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012, 97:416-422.